Study guide
7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
Key Takeaways Explain This Topic AI
USP <797> Section 19 requires SOPs for handling, storing, packaging and transporting CSPs, and documented training for everyone who does those tasks inside the facility.
CSP storage areas are temperature-controlled and monitored every day, manually or continuously. Monitoring devices are verified at least every 12 months (or per the manufacturer), and a designated person decides whether a CSP exposed outside its limits can still be used; if that cannot be determined, it is discarded.
Packaging and transport are chosen from the product's specifications, vendor information and the mode of transport. Light-sensitive CSPs get light-resistant packaging, temperature-sensitive ones get insulated containers, and special handling instructions go on the outside of the container.
BUDs are not additive across storage conditions: a thawed CSP cannot be refrozen, cannot be thawed in a microwave, and its total storage time cannot exceed the original BUD for its labeled storage condition.
Liquid hazardous drugs and all antineoplastic HDs must never be sent through pneumatic tubes (USP <800>), and CSPs returned with a complaint are quarantined until destroyed after the investigation.
Last updated: September 2026
7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
A CSP can be compounded perfectly and still fail the patient. It can be left warm in a delivery bin, shaken apart in a pneumatic tube, frozen twice, or given after its BUD. The BCSCP outline (task 1B6) covers the handling of finished CSPs through receipt, transfer, storage, transport and disposal. USP <797> Section 19 is the core standard.
Training and SOPs (Section 19)
The facility's SOPs must describe how CSPs are handled, stored, packaged and transported . Everyone who does these tasks inside the facility must be trained on the relevant SOPs, and that training must be documented. USP's FAQ adds that people who only receive, deliver or store CSPs still need documented competence, defined by the organization.
Storage and temperature control (19.1)
Requirement Detail
Controlled temperature area Established and monitored so each CSP stays within its range (USP <659> definitions: controlled room temperature 20-25 °C; refrigerator 2-8 °C; freezer -25 to -10 °C)
Monitoring frequency Each day , manually or with a continuous recorder. USP's FAQ accepts recording on Monday for a site closed at the weekend
- Records A temperature log, or retrievable data in the continuous device
- Device accuracy Verified at least every 12 months, or as the manufacturer requires
Excursions Detected and minimized. When a CSP is known to have been exposed outside its limits, a designated person decides from literature or testing whether it keeps its integrity. If that cannot be determined, it is discarded
Thawing and changing storage conditions (14.2.4)
Containers for frozen CSPs must withstand freezing without cracking.
Thaw under appropriate conditions, for example in a refrigerator. Never use a microwave.
Never refreeze a thawed CSP.
A CSP may move between conditions (frozen, then refrigerated, then room temperature), but its storage time must not exceed the original BUD for its labeled storage condition , and BUDs are not additive . USP's FAQ gives two examples. A room-temperature CSP cannot be refrigerated or frozen to extend its BUD. A frozen CSP's BUD cannot be extended by storage at room temperature after thawing.
Packaging (19.2)
The facility chooses shipping containers and packaging materials based on the product specifications, vendor information and the mode of transport:
- Tamper-evident closures where needed
- Light-resistant packaging for light-sensitive CSPs
- Insulated containers (coolers, gel packs, temperature indicators) for CSPs sensitive to temperature changes
- Protection against breakage and leaks, especially for glass and for hazardous drugs
- Shipping and transport (19.3)
Choose transport that will deliver properly packed CSPs undamaged, sterile and stable .
When a CSP needs special handling, for example because of stability concerns, put specific handling instructions on the outside of the container .
Pneumatic tubes: USP <800> forbids sending any liquid HD, or any antineoplastic HD , by pneumatic tube. For other CSPs, the facility decides what may go by tube. Many exclude proteins and monoclonal antibodies that can be damaged by agitation, glass containers, and high-alert drugs.
Home infusion: Validated shipping containers keep the temperature for the whole route. Patients are told how to store the CSP (for example in the refrigerator, away from food), how to bring it to room temperature before infusion, and what to do if it arrives warm or damaged (see 9.3).
Receiving CSPs from outside suppliers
CSPs bought from a 503B outsourcing facility, or from another pharmacy, are inspected on receipt. Check the shipping container and temperature indicators, the labels (including "This is a compounded drug" for 503B products), lot numbers, expiration dates or BUDs, and the physical condition of the product. Store them under the labeled conditions. Anything exposed to temperatures outside its range is quarantined and evaluated, or returned under the supplier's instructions.
Returns, recalls and disposal
Situation Handling
CSP returned with a complaint Quarantined until destroyed, after the investigation is complete (USP <797> 18.2)
CSP recalled Quarantined; remaining stock recovered; disposal and reconciliation documented (USP <797> 18.1; see 12.2)
CSP past its BUD Removed from stock and discarded; never relabeled with a new BUD
Unused CSP returned from a patient care area Re-dispensed only if SOPs allow and storage and integrity can be confirmed; otherwise discarded
Hazardous drug CSPs and trace waste Handled under RCRA and EPA Subpart P rules; bulk HD waste goes to hazardous waste containers; never sewered (see 12.3)
Controlled substance CSPs (for example PCA opioids) Wastage witnessed and documented under DEA and state rules; inventory destruction documented as required
Exam traps
"It was only warm for a few hours, so extend nothing and use it." That is wrong. A designated person must evaluate the excursion, and if integrity cannot be determined, the CSP is discarded.
Refreezing a thawed PN bag, or adding refrigerated time on top of a frozen BUD, is not allowed.
Sending a methotrexate syringe by pneumatic tube is not allowed.